Opus Genetics (IRD) Enterprise Value (2010 - 2026)
Opus Genetics (IRD) reported Enterprise Value of -$60.0 million for Q1 2026, down 43.44% year-over-year from -$106.0 million in Q1 2025, and down 32.97% quarter-over-quarter from -$45.1 million in Q4 2025.
Opus Genetics (IRD) Enterprise Value (2010 - 2026) Analysis & Trends
Opus Genetics (IRD) has 17 years of Enterprise Value data on file, last reported at -$60.0 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$60.0 million, down 43.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$60.0 million (down 43.44% YoY), and the FY2025 annual result was -$45.1 million, down 48.7% from the prior year.
- Enterprise Value fell to -$60.0 million in Q1 2026 per IRD's latest filing, from -$45.1 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$14.0 million in Q3 2022 and troughed at -$60.0 million in Q1 2026.
- A 5-year average of -$37.1 million and a median of -$40.0 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2023 and 2024: Enterprise Value plunged 203.89% in 2023, then surged 39.97% in 2024.
- A 5-year view of Enterprise Value shows it stood at -$42.7 million in 2022, then dropped by 18.35% to -$50.5 million in 2023, then surged by 39.97% to -$30.3 million in 2024, then plunged by 48.7% to -$45.1 million in 2025, then plunged by 32.97% to -$60.0 million in 2026.
- Business Quant data shows IRD's Enterprise Value at -$60.0 million in Q1 2026, -$45.1 million in Q4 2025, and -$30.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | Opus Genetics | 355.39 Mn | 295.43 Mn | - | -59.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -59.96 Mn |
| Dec 31, 2025 | -45.09 Mn |
| Sep 30, 2025 | -30.80 Mn |
| Jun 30, 2025 | -32.43 Mn |
| Mar 31, 2025 | -41.80 Mn |
| Dec 31, 2024 | -30.32 Mn |
| Sep 30, 2024 | -36.60 Mn |
| Jun 30, 2024 | -41.41 Mn |
| Mar 31, 2024 | -47.17 Mn |
| Dec 31, 2023 | -50.52 Mn |
| Sep 30, 2023 | -42.41 Mn |
| Jun 30, 2023 | -40.02 Mn |
| Mar 31, 2023 | -39.01 Mn |
| Dec 31, 2022 | -42.68 Mn |
| Sep 30, 2022 | -13.96 Mn |
| Jun 30, 2022 | -17.15 Mn |
| Mar 31, 2022 | -19.38 Mn |
| Dec 31, 2021 | -24.75 Mn |
| Sep 30, 2021 | -22.63 Mn |
| Jun 30, 2021 | -24.23 Mn |